The Effects of a Novel MEK Inhibitor PD184161 on MEK-ERK Signaling and Growth in Human Liver Cancer

The MEK-ERK growth signaling pathway is important in human hepatocellular carcinoma (HCC). To evaluate the targeting of this pathway in HCC, we characterized a novel, orally-active MEK inhibitor, PD184161, using human HCC cells (HepG2, Hep3B, PLC, and SKHep) and in vivo human tumor xenografts. PD184...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Patrick J. Klein, C. Max Schmidt, Chad A. Wiesenauer, Jennifer N. Choi, Earl A. Gage, Michele T. Yip-Schneider, Eric A. Wiebke, Yufang Wang, Charles Omer, Judith S. Sebolt-Leopold
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2006-01-01
Serie:Neoplasia: An International Journal for Oncology Research
Soggetti:
Hepatocellular carcinoma
liver cancer
MEK
ERK
PD184161
Accesso online:http://www.sciencedirect.com/science/article/pii/S1476558606800357
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi